Compare Beyond Meat Inc (BYND) vs Stryker Corporation (SYK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Beyond Meat Inc vs Stryker Corporation — how do they compare? Beyond Meat Inc trades at $0.41 (market cap $215.41M), while Stryker Corporation trades at $346.82 (market cap $133.54B). The key difference: Stryker Corporation is far larger — about 619.9× Beyond Meat Inc's market cap, and Stryker Corporation pays a 1.01% dividend while Beyond Meat Inc pays none. Which is the better fit depends on your goals.
| BYND | SYK | |
|---|---|---|
Market Cap | $215.41M | $133.54B |
Sector | Consumer Staples | Technology |
52-Week High | $3.62 | $394.34 |
52-Week Low | $0.42 | $282.58 |
Enterprise Value | $455.69M | $145.01B |
Dividend Yield | — | 1.01% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Beyond Meat (BYND) trades at $0.4066, down 21.81% amid a 1-for-30 reverse stock split announcement. The stock is technically bearish with negative cash flow from operations, though recent quarters show mixed earnings beats. Revenue has declined from $419M in 2022 to $275M in 2025, but net income turned positive at $178M in 2025, driven by a one-time gain. Analyst sentiment is heavily skewed toward sell ratings, reflecting skepticism about the company's turnaround efforts and persistent cash burn.
The outlook remains challenging due to declining sales, high cash burn, and weak investor confidence. While valuation ratios like P/S of 0.61 appear low, the risk of further dilution or delisting outweighs potential upside. Key risks include execution missteps and competitive pressure in the plant-based food sector.
Stryker (SYK) trades at $347.21, up 0.4% today, with a bullish technical outlook supported by moving averages. The stock shows strong fundamentals, including a 9% organic sales growth in Q2 2026 and a net income margin of 14.43%. Recent news highlights recovery from a cybersecurity incident and the launch of Mako RPS, expanding its robotic surgery portfolio. Analyst consensus is overwhelmingly positive, with 74% recommending Buy and a price target of $379.44.
The outlook for SYK is favorable, driven by robust earnings growth and strategic product launches. Key risks include cybersecurity vulnerabilities and margin pressures from tariffs. With no sell ratings and strong institutional support, the stock presents a compelling opportunity for growth-oriented investors, though monitoring quarterly execution remains critical.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Beyond Meat Inc
Beyond Meat is a provider of plant-based meats, such as burgers, sausage, ground beef, and chicken. Unlike other vegetarian products, Beyond Meat seeks to replicate the look, cook, and taste of meat, is targeted to omnivores and vegetarians alike, and is sold in the meat case. The products are widely available across the U.S. and Canada and in 83 additional countries as well. International revenue represented 31% of 2021 sales. The firm's products are available in retail stores and the food-service channel. In 2019, before the pandemic struck, sales were evenly split between these two channels, although mix stood at 70% retail/30% food service in 2021. We think the recovery from the crisis and new deals with McDonald's and Yum Brands will return food-service sales to nearly 50% in time.
Read more on BYND →About Stryker Corporation
Stryker is a global leader in medical technology, specializing in Orthopaedics, MedSurg, and Neurotechnology. It is renowned for its highly decentralized business model, which empowers 22 specialized business units to drive innovation and category leadership. With its market-leading Mako SmartRobotics™ platform and a relentless M&A strategy, Stryker provides a comprehensive ecosystem of connected surgical tools, implants, and digital solutions that improve both clinical and financial outcomes for hospitals worldwide.
Read more on SYK →
